The Pharming Group NV has confirmed plans to submit a new marketing authorisation application for its lead drug, Rhucin, to the European Medicines Agency in September 2009 and thereafter, to the US Food and Drug Administration. ---Subscribe to MedNous to access this article--- Company News
